Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia

Journal of Atherosclerosis and Thrombosis

Volumn 19, Issue 12, 2012, Pages 1093-1101

  Kikuchi, Kaori ^a   Nezu, Uru ^a   Inazumi, Koji ^a   Miyazaki, Takashi ^a   Ono, Kanako ^a   Orime, Kazuki ^a   Shirakawa, Jun ^a   Sato, Koichiro ^a   Koike, Hirofumi ^b   Wakasugi, Tadashi ^b   Sato, Misako ^b   Kawakami, Chihiro ^a   Watanabe, Shinichiro ^b   Yamakawa, Tadashi ^b   Terauchi, Yasuo ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

Author keywords

Ezetimibe; Hyperglycaemia; Hyperlipidaemia

Indexed keywords

CHOLESTEROL; EZETIMIBE; FATTY ACID; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOREACTIVE INSULIN; LACTOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ENCAPSULATION; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; MALE; OBESITY; POSTPRANDIAL STATE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-48; AZETIDINES; BLOOD GLUCOSE; CHOLESTEROL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GLUCOSE; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; INTESTINES; LIPID METABOLISM; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OBESITY; PLACEBOS; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; TIME FACTORS; TRIGLYCERIDES;

EID: 84871738435     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.12427     Document Type: Article

References (33)

1. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352: 1425-1435.
2. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP: Pleiotropic effects of statins--clinical evidence. Curr Pham Des, 2009; 15: 479-489.
3. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y: Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet, 2006; 368: 1155-1163.
4. Tajima N, Kurata H, Nakaya N, Mizuno K, Ohashi Y, Kushiro T, Teramoto T, Uchiyama S, Nakamura H: Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis, 2008; 199: 455-462.
5. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 350: 1495-1504.
6. Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, Shimamoto T, Iida M, Komachi Y: Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol, 2001; 153: 490-499.
7. Eberly LE, Stamler J, Neaton JD: Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med, 2003; 163: 1077-1083.
8. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short-and long-term simvastatin treatment. Circulation, 2002; 106: 1211-1218.
9. Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, Jackson SK, Lewis MJ, Frenneaux MP, Rees A: Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation, 2000; 101: 1773-1779.
10. Grieve DJ, Avella MA, Elliott J, Botham KM: The influence of chylomicron remnants on endothelial cell function in the isolated perfused rat aorta. Atherosclerosis, 1998; 139: 273-281.
11. Funada J, Sekiya M, Otani T, Watanabe K, Sato M, Akutsu H: The close relationship between postprandial remnant metabolism and insulin resistance. Atherosclerosis, 2004; 172: 151-154.
12. Johanson EH, Jansson PA, Gustafson B, Lönn L, Smith U, Taskinen MR, Axelsen M: Early alterations in the postprandial VLDL1 apoB-100 and apoB-48 metabolism in men with strong heredity for type 2 diabetes. J Intern Med, 2004; 255: 273-279.
13. Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP: Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract, 2003; 57: 363-368.
14. Saito Y, Yamada N, Nakatani N, Teramoto T, Oikawa S, Yamashita S, Tsushima M, Nakashima M, Yamamoto A: Phase III clinical study of ezetimibe-double-blind comparative study with colestilan. J Clin Ther Med, 2007; 23: 493-522.
15. Masuda D, Nakagawa-Toyama Y, Nakatani K, Inagaki M, Tsubakio-Yamamoto K, Sandoval JC, Ohama T, Nishida M, Ishigami M, Yamashita S: Ezetimibe improves postprandial hyperlipidaemia in patients with type II hyperlipidaemia. Eur J Clin Invest, 2009; 39: 689-698.
16. Hiramitsu S, Ishiguro Y, Matsuyama H, Yamada K, Kato K, Noba M, Uemura A, Yoshida S, Matsubara Y, Kani A, Hasegawa K, Hishida H, Ozaki Y: The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. J Atheroscler Thromb, 2010; 17: 106-114.
17. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, Ishii H, Yoshida M: Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett, 2007; 581: 5664-5670.
18. Labonté ED, Camarota LM, Rojas JC, Jandacek RJ, Gilham DE, Davies JP, Ioannou YA, Tso P, Hui DY, Howles PN: Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe treated and Npc1l1-/-mice. Am J Physiol Gastrointest Liver Physiol, 2008; 295: 776-783.
19. Assy N, Grozovski M, Bersudsky I, Szvalb S, Hussein O: Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J Gastroenterol, 2006; 12: 4369-4376.
20. Zheng S, Hoos L, Cook J, Tetzloff G, Davis H Jr, van Heek M, Hwa JJ: Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol, 2008; 584: 118-124.
21. Browning JD, Horton JD: Molecular mediators of hepatic steatosis and liver injury. J Clin Invest, 2004; 114: 147-152.
22. González-Ortiz M, Martínez-Abundis E, Kam-Ramos AM, Hernández-Salazar E, Ramos-Zavala MG: Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Cardiovasc Drug Ther, 2006; 20: 143-146.
23. Yang L, Choi JM, Kim L, Kim BJ, Sohn JH, Kim WJ, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Kim SW, Park CY: Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes. Biochem Biophys Res Commun, 2011; 407: 153-157.
24. Yang L, Li X, Ji Y, Kohan AB, Wang DQ, Howles PN, Hui DY, Lai J, Tso P: Effect of ezetimibe on incretin secretion in response to the intestinal absorption of a mixed meal. Am J Physiol Gastrointest Liver Physiol, 2010; 299: 1003-1011.
25. Muraoka T, Aoki K, Iwasaki T, Shinoda K, Nakamura A, Aburatani H, Mori S, Tokuyama K, Kubota N, Kadowaki T, Terauchi Y: Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism, 2011; 60: 617-628.
26. Nozue T, Michishita I, Mizuguchi I: Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. J Atheroscler Thromb, 2010; 17: 37-44.
27. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Visseren FL: The effectof statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis, 2009; 202: 216-224.
28. Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, Suzuki K, Mawatari H, Kirikoshi H, Inamori M, Saito S, Iwasaki T, Terauchi Y, Kubota K, Maeyama S, Nakajima A: Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. Hepatol Res, 2010; 40: 613-621.
29. Yang SJ, Choi JM, Kim L, Kim BJ, Sohn JH, Kim WJ, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Kim SW, Park CY: Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes. Biochem Biophys Res Commun, 2011; 407: 153-157.
30. van Heek M, Austin TM, Farley C, Cook JA, Tetzloff GG, Davis HR: Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes, 2001; 50: 1330-1335.
31. Sager PT, Capece R, Lipka L, Strony J, Yang B, Suresh R, Mitchel Y, Veltri E: Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis, 2005; 179: 361-367.
32. Bulut D, Hanefeld C, Bulut-Streich N, Graf C, Mügge A, Spiecker M: Endothelial function in the forearm circulation of patients with the metabolic syndrome--effect of different lipid-lowering regimens. Cardiology, 2005; 104: 176-180.
33. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM: Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J, 2008; 156: 826-832